Medivir’s CEO increases his shareholding in the company

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the company’s CEO, Niklas Prager, has bought 10,000 class B shares in Medivir at an acquisition price of approximately SEK 825.000. The share purchase has occurred within the framework of an insurance arrangement and will consequently be made public through this press release and not be reported to the Swedish Financial Supervisory Authority’s insider register.

For more information please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.


About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Documents & Links